Evaluation of Macitentan in Patients With Eisenmenger Syndrome Results From the Randomized, Controlled MAESTRO Study

TL;DR: Praha f Interní kardiologická klinika, Fakultní nemocnice Brno a Centrum komplexní péče o vrozené srdeční vady v dospělosti, Brno

TL;DR: The ESC/ERS pulmonary hypertension guidelines as mentioned in this paper incorporate changes and adaptations focusing on clinical management, which are made in consultation with the patient and caregiver as appropriate, based on what they consider to be the most appropriate in the circumstances.

TL;DR: The role of endothelin in cardiovascular diseases such as arterial hypertension, preecclampsia, coronary atherosclerosis, myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) caused by spontaneous coronary artery dissection, Takotsubo syndrome, and heart failure is discussed.

TL;DR: In this article, the authors present new constructs in CHD research, such as long-term trajectories and a life course epidemiology framework, focusing on a precision health, integrating current knowledge on the genome, phenome, and environome across the CHD lifespan.

TL;DR: In this article, guidelines summarize and evaluate all available evidence on a particular issue, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk-benefit ratio of particular diagnostic or therapeutic means.

TL;DR: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.

TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.

TL;DR: Inhaled Iloprost is an effective therapy for patients with severe pulmonary hypertension and hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation, and were significantly worse in the placebo group.